Last reviewed · How we verify
Planned Parenthood League of Massachusetts — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Mifepristone plus two doses Misoprostol | Mifepristone plus two doses Misoprostol | phase 3 | Progesterone receptor antagonist + prostaglandin analog combination | Progesterone receptor (PR); prostaglandin E1 receptor (EP receptor) | Reproductive Health / Obstetrics | |
| Mifepristone plus one dose Misoprostol | Mifepristone plus one dose Misoprostol | phase 3 | Progesterone antagonist + prostaglandin analog | Progesterone receptor (PR) + prostaglandin E1 receptor (EP receptor) | Reproductive Health / Obstetrics |
Therapeutic area mix
- Reproductive Health / Obstetrics · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Gynuity Health Projects · 1 shared drug class
- Hadassah Medical Organization · 1 shared drug class
- Reproductive Health Training Center of the Republic of Moldova · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Planned Parenthood League of Massachusetts:
- Planned Parenthood League of Massachusetts pipeline updates — RSS
- Planned Parenthood League of Massachusetts pipeline updates — Atom
- Planned Parenthood League of Massachusetts pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Planned Parenthood League of Massachusetts — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/planned-parenthood-league-of-massachusetts. Accessed 2026-05-17.